SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.
Revenue of SeqLL Inc. (SQL)
Revenue in 2022 (TTM): $1.18 K
According to SeqLL Inc.'s latest financial reports the company's current revenue (TTM) is $1.18 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of SeqLL Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $1.18 K | $487 | $-3,864,332 | $-4,094,833 | $-4,192,518 |
| 2021 | $48.02 K | $-9,669 | $-2,467,953 | $-3,703,558 | $-3,906,078 |
| 2020 | $50.59 K | $-120,215 | $-649,397 | $-1,045,353 | $-1,524,116 |
| 2019 | $160.48 K | $-59,283 | $-2,169,767 | $-2,473,549 | $-2,655,799 |
| 2018 | $779.07 K | $104.79 K | $-1,898,770 | $-2,888,017 | $-2,888,017 |
| 2017 | $1.34 M | $254.23 K | $-1,454,558 | $-1,706,934 | $-1,706,934 |